Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail aims to control follicular lymphoma without chemo

NCT ID NCT07585747

First seen May 15, 2026 · Last updated May 23, 2026 · Updated 2 times

Summary

This study tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) as a first treatment for people with follicular lymphoma, a slow-growing blood cancer. The goal is to see how well the drugs shrink or eliminate tumors and to check for side effects. About 27 newly diagnosed adults who need treatment will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Institute of Hematology & Blood Diseases Hospital, China

    Tianjin, Tianjin Municipality, 300020, China

  • Qilu Hospital of Shandong Province

    Jinan, Shandong, China

    Contact Phone: •••-•••-••••

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China

    Contact Phone: •••-•••-••••

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330000, China

Conditions

Explore the condition pages connected to this study.